Efficient induction of cytotoxic T lymphocytes specific to hepatocellular carcinoma using HLA-A2-restricted MAGE-n peptide in vitro
- 10 August 2004
- journal article
- research article
- Published by Elsevier in Cancer Letters
- Vol. 211 (2) , 219-225
- https://doi.org/10.1016/j.canlet.2004.02.013
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Screening for Hepatocellular CarcinomaJournal of Clinical Gastroenterology, 2002
- Treatment of non‐resectable hepatocellular carcinoma with autologous tumor‐pulsed dendritic cellsJournal of Gastroenterology and Hepatology, 2002
- Generation of CTL Recognizing an HLA-A*0201-Restricted Epitope Shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 Tumor Antigens: Implication in a Broad-Spectrum Tumor ImmunotherapyThe Journal of Immunology, 2002
- Immunotherapy of hepatocellular carcinomaExpert Opinion on Biological Therapy, 2002
- Induction of systemic CTL responses in melanoma patients by dendritic cell vaccination: Cessation of CTL responses is associated with disease progressionInternational Journal of Cancer, 2001
- Analysis of MAGE-3 derived synthetic peptide as a human lung cancer antigen recognized by cytotoxic T lymphocytesInternational Journal of Clinical Oncology, 2001
- Efficient induction of antitumor cytoxic T lymphocytes from a healthy donor using HLA-A2-restricted MAGE-3 peptide in vitroCancer Immunology, Immunotherapy, 1997
- Induction of peptide‐specific primary cytotoxic T lymphocyte responses from human peripheral bloodEuropean Journal of Immunology, 1995
- BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytesImmunity, 1995
- A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human MelanomaScience, 1991